Future Oncology
Volume 20, 2024 - Issue 13
Short Communication
Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union
Lucjan Wyrwicz1 Department of Oncology & Radiotherapy, Maria Sklodowska Curie National Cancer Research Institute, Warsaw, PolandCorrespondence[email protected]
https://orcid.org/0000-0003-0808-6892
https://orcid.org/0000-0003-0808-6892, César A Rodríguez Sánchez2 Department of Medical Oncology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spainhttps://orcid.org/0000-0003-3484-4829
https://orcid.org/0000-0003-3484-4829, Pedro Sánchez-Rovira3 Department of Oncology, University Hospital of Jaén, Jaén, Spainhttps://orcid.org/0000-0003-2658-1467
https://orcid.org/0000-0003-2658-1467, Sandra Lewis4 Global Medical Affairs, Amgen Inc., Thousand Oaks, CA91320, USAhttps://orcid.org/0009-0005-0175-2591
https://orcid.org/0009-0005-0175-2591, Darcie Sandschafer4 Global Medical Affairs, Amgen Inc., Thousand Oaks, CA91320, USAhttps://orcid.org/0009-0009-8531-9726
https://orcid.org/0009-0009-8531-9726 & 